The present invention is directed to a method of replacing collagen broken down during physical activity using a novel dietary supplement. The supplement composition of the present invention comprises collagen, glutamine, taurine, and, optionally, the nine essential amino acids. The uptake of collagen is enhanced using this combination of components to levels substantially near the pre-workout levels.

Disclosed embodiments provide nutritional compositions and methods of enhancing maturation of an infant's brain. The methods include the step of administering to the infant a nutritional composition comprising a protein with a degree of hydrolysis of 10% to 75% in combination with at least one of a monoglyceride, a free fatty acid, a salt of a free fatty acid, a phospholipid, and cholesterol.

Disclosed embodiments provide nutritional compositions and methods of enhancing maturation of an infant's brain. The methods include the step of administering to the infant a nutritional composition comprising a protein with a degree of hydrolysis of 10% to 75% in combination with at least one of a monoglyceride, a free fatty acid, a salt of a free fatty acid, a phospholipid, and cholesterol.

The present invention relates to a saccharide syrup composition comprising an organic acid or its salt and an oligosaccharide, and more specifically, the saccharide syrup composition comprises allulose.

The present invention relates to a saccharide syrup composition comprising an organic acid or its salt and an oligosaccharide, and more specifically, the saccharide syrup composition comprises allulose.

The present invention relates to a fertility-enhancing composition for human male fertility therapy and a method for using the same to improve or enhance human male fertility. The nutritional supplement composition of the invention includes an effective amount of L-carnitine tartrate, coenzyme Q10, methylcobalamin, N-acetyl L-cysteine, and grape seed extract.

The present invention relates to a fertility-enhancing composition for human male fertility therapy and a method for using the same to improve or enhance human male fertility. The nutritional supplement composition of the invention includes an effective amount of L-carnitine tartrate, coenzyme Q10, methylcobalamin, N-acetyl L-cysteine, and grape seed extract.

A reduction treatment agent made of a powder with a particle size within a range of 1500 to 3000 mesh, the powder containing: 20 to 40 parts of a mixed-oxide powder containing magnesium oxide and zinc oxide; and 60 to 80 parts of an organic acid powder containing calcium, ascorbic acid, citric acid and salt. The reduction treatment agent may further contain one to six kinds of metal powder selected from the group of copper, molybdenum, nickel, cobalt, iron and aluminum, each in an amount of one part. Due to this configuration, the reduction treatment agent can be easily mixed with various substances when added to those substances. Even if the target substance is not water, the agent can entirely and uniformly change that substance into a reduced state. Additionally, the reduction treatment agent can act as a surfactant, and therefore, can be used as cosmetics or food.

A reduction treatment agent made of a powder with a particle size within a range of 1500 to 3000 mesh, the powder containing: 20 to 40 parts of a mixed-oxide powder containing magnesium oxide and zinc oxide; and 60 to 80 parts of an organic acid powder containing calcium, ascorbic acid, citric acid and salt. The reduction treatment agent may further contain one to six kinds of metal powder selected from the group of copper, molybdenum, nickel, cobalt, iron and aluminum, each in an amount of one part. Due to this configuration, the reduction treatment agent can be easily mixed with various substances when added to those substances. Even if the target substance is not water, the agent can entirely and uniformly change that substance into a reduced state. Additionally, the reduction treatment agent can act as a surfactant, and therefore, can be used as cosmetics or food.

Methods for treatment of chronic liver disease and reversing liver fibrosis are provided. These treatments may be achieved using a medical food composition. The medical food is configured specifically for those having chronic liver disease to provide for specific nutritional requirements caused by the chronic liver disease. Testing of the treated patient allows for tracking of progress and to determine if the liver fibrosis is reversed.